NCT00962533CompletedPhase 4
A Two-year, Randomized, Controlled, Open-label, Virologic Response Adaptive Design, Multicenter Study to Optimize Antiviral Efficacy of Telbivudine in Adult Patients With HBeAg Positive Chronic Hepatitis B (EFFORT Study)
Nanfang Hospital, Southern Medical University24 sites in 1 country606 target enrollmentStarted: August 2009Last updated:
Conditions
Interventions
Drugs
Trial Snapshot
- Phase
- Phase 4
- Status
- Completed
- Enrollment
- 606
- Locations
- 24
- Primary Endpoint
- To demonstrate the percentage of patients achieving HBV DNA< 300copies/mL at Week 104 in Group I is superior than that in Group II
Study Overview
Brief Summary
The purpose of this trial is to prove that the strategy of treatment adjustment at W24 according to virological response based on ROADMAP concept is better than standard of care strategy.
Study Design
- Study Type
- Interventional
- Allocation
- Randomized
- Intervention Model
- Parallel
- Primary Purpose
- Treatment
- Masking
- None
Eligibility Criteria
- Ages
- 18 Years to 65 Years (Adult, Older Adult)
- Sex
- All
- Accepts Healthy Volunteers
- No
Inclusion Criteria
- •Male or female, from 18 (inclusive) to 65 (inclusive) years of age
- •HBsAg and HBeAg positive for over six months
- •Patient is willing and able to comply with the study drug regimen and all other study requirements
- •Patients must give written informed consent before any assessment is performed
Exclusion Criteria
- •Detected M204I/V, N236T, A181V/T mutation in patient serum HBV DNA at Screening visit
- •Patient has a history of or clinical signs/symptoms of hepatic decompensation
- •Patient has a history of hepatocellular carcinoma (HCC) or findings suggestive of possible HCC
- •Other protocol-defined inclusion/exclusion criteria may apply
Arms & Interventions
ROADMAP Group (Group I)
Experimental
Patients were to take telbivudine 600 mg orally daily from Baseline.At Week 24, patients in Group I were split into Group I-A or Group I-B based on their virologic load:
- Group I-A: This group of patients was those with HBV DNA ≥300 copies/mL at Week 24 and adefovir was to be added at Week 28;
- Group I-B: This group of patients was those with HBV DNA <300 copies/mL at Week 24. Telbivudine monotherapy was to be continued until there was a viral breakthrough (confirmed by two examinations with at least 1 month interval with compliance factor excluded) and then adefovir was to be added;
The total treatment duration was 104 weeks.
Intervention: telbivudine (Drug)
SOC (Standard of Care) Group (Group II)
Active Comparator
patients were to take telbivudine 600 mg monotherapy from Baseline until Week 104. If viral breakthrough (defined as HBV DNA 1 log10 above nadir) was confirmed (by two examinations with at least a 1 month interval with compliance factor excluded), adefovir 10 mg daily was to be added.
Intervention: telbivudine (Drug)
Outcomes
Primary Outcomes
To demonstrate the percentage of patients achieving HBV DNA< 300copies/mL at Week 104 in Group I is superior than that in Group II
Time Frame: Week 104
Secondary Outcomes
- Percentage of patients achieving HBV DNA <60IU/mL (300copies/mL) at Week 52(week 52)
- Serum HBV DNA reduction from baseline at week 104(week 104)
- Percentage of patients with HBeAg loss & HBeAg seroconversion at week104 in patients with HBeAg positive at baseline(week 104)
- Percentage of patients with HBV DNA<300copies/mL AND HBeAg loss or seroconversion at Week 104 in patients with positive HBeAg at baseline(week 104)
- Serum HBV DNA reduction from baseline at week 52(week 52)
Investigators
Study Sites (24)
Loading locations...
Similar Trials
Completed
Phase 2
An Efficacy, Safety, and Pharmacokinetics Study of JNJ-56136379 in Participants With Chronic Hepatitis B Virus InfectionHepatitis BNCT03361956Janssen Sciences Ireland UC232
Recruiting
Not Applicable
Modified Pivotal Response Treatment for Insistence on Sameness in Autistic YouthRestricted BehaviorAutism Spectrum DisorderAutismNCT06362733Stanford University44
Completed
Phase 2
12 Week Evaluation of the Safety and Efficacy of a Flexible Dose of CP-526,555 and Placebo for Smoking CessationSmoking CessationNCT00150228Pfizer300
Completed
Phase 2
A Study of the Safety and Effectiveness of a R256918 in Patients With Type 2 DiabetesDiabetes Mellitus, Type 2Endocrine System DiseasesNutritional and Metabolic DiseasesDiabetes MellitusNCT00672386Johnson & Johnson Pharmaceutical Research & Development, L.L.C.352
Completed
Phase 4
Long-term Efficacy, Safety and Tolerability of Pramipexole in Patients With Idiopathic Moderate to Severe Restless Legs Syndrome (RLS)Restless Legs SyndromeNCT00472199Boehringer Ingelheim331